Navigation Links
Redox-active iron is a sensor of cognitive impairment associated with Alzheimer's disease
Date:4/4/2008

April 4, 2008 -- An innovative discovery has been reported that highlights the problems that oxidative stress resulting from iron cumulated in the human brain can generate in relation with the pathogenesis of Alzheimer's disease (AD), the brain disorder affecting almost 30 million throughout the world. The results of research carried out by Drs. Manuel Lavados, Patricio Fuentes and Leonel Rojo from the laboratory of Professor Dr. R.B. Maccioni of the School of Medicine of the University of Chile, and the International Center for Biomedicine, together with his colleagues, appeared recently in Volume 13, Issue 2 of the prestigious Journal of Alzheimer's Disease (JAD). For several decades this laboratory has been acknowledged as one of the main world contributors to our understanding of AD and the development of tools for its early diagnosis.

The study focuses on the reactivity of iron in the cerebrospinal fluid (CSF) and its correlation with the severity of cognitive decline in both patients with AD and subjects diagnosed with mild cognitive impairment (MCI). Different stages of cognitive and functional impairment are associated with changes in CSF reactive iron. CSF samples from 56 seniors classified into 4 groups according to their scores on the Clinical Dementia Rating scale (CDR) were compared in respect to the levels of a particular form of iron, the redox-active iron.

Interestingly, redox-active iron levels in the CSF increased with the degree of cognitive impairment from normal to MCI subjects, while AD patients showed an abrupt decrease to levels close to zero. However, no difference in the total CSF iron was found between the different groups. Given the relevance of oxidative damage in neurodegeneration occuring during the course of dementia, the development of cognitive and functional decline appears to be associated with the presence of redox-active iron in the CSF. The abrupt decrease in redox-active iron found in patients affected with AD may represent a terminal situation, whereby the central nervous system attempts to minimize iron-associated toxicity.

A possible mechanism to explain the decrease of redox-active CSF iron during the course of the disease could be the sequestration of this metal by the aggregation of a brain component called amyloid peptides (A) into the senile plaques, anomalous structures where cumulative iron has been found. High redox-active CSF iron levels could increase the production of the amyloid- protein precursor (APP) in the neuronal membrane, while the soluble form of APP (A peptide) could act as an iron chelator promoting A peptides aggregation into the senile plaques. The suggested mechanism could represent a homeostatic process by the brain that fights to reduce the cascade of cellular insults in AD, in order to regulate the CSF iron levels and its toxicity. These findings indicate that the decrease in redox-active CSF iron may correspond to a final late effort by brain cells to decrease oxidative stress mediated by iron.

This discovery offers the possibility to monitor iron levels in the CSF in relation with cognitive impairment and perhaps be used as part of a battery of biomarkers for an early diagnosis of these disorders, thus facilitating the appropriate treatment to patients and increasing their quality of life.


'/>"/>

Contact: Astrid Engelen
a.engelen@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Biosensors to probe the metals menace
3. Leading-edge body sensor could help produce sporting champions
4. Tiny Sensor Could Spot Cancer Early
5. Area deep within the brain found to play role in sensory perception
6. Study Offers Insights Into Sensory Perceptions
7. GainSpan Unveils Wi-Fi(R) Sensor Network Solution With Years of Battery Life
8. Biometric sensors no dirtier than doorknobs, study finds
9. Scientists Spot Eyes Motion Sensors
10. Space sensors shed new light on air quality
11. Investigating causes of asthma attacks: New sensor system monitors environmental exposure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... September 26, 2017 , ... Atmosera , a ... Management as a Service (RMaaS) to automate the deployment of websites and ... companies, e-tailers, and web development agencies who want to improve time-to-revenue with a ...
(Date:9/26/2017)... ... , ... As the holiday season nears, best deals online website, ... to find tips and stories for products and services savings. With a lot of ... deals. The deals are organized by categories so can easily find what you’re looking ...
(Date:9/26/2017)... Falls Church, VA (PRWEB) , ... September 26, 2017 , ... ... FDAnews and Cerulean Associates LLC **, Dec. 5-6, 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity ... its investigators: “If initial findings indicate the firm’s electronic records may not be trustworthy ...
(Date:9/26/2017)... ... September 26, 2017 , ... Autism Learning ... Northern Colorado. Aspire Autism, A Division of Autism Learning Partners, will be the ... Aspire provides center based Autism services in Broomfield and will continue to operate ...
(Date:9/26/2017)... ... September 26, 2017 , ... The Organizing Committee ... tactical plans for Pittcon 2018. As of July 1, Adrian C. Michael, Ph.D. ... named vice president, Charles Gardner, (ChemImage Corporation) and selected chairs. , ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... BioLife Solutions , Inc. (NASDAQ: BLFS ), the ... and tissue hypothermic storage and cryopreservation freeze ... and CEO, will be presenting at two investment conferences in ... th Annual Global Investment Conference on Tuesday, September 12th, ... conference is being held at the New York Palace Hotel ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: